NCT07217587 2026-04-13
EPIC
Janssen Research & Development, LLC
Phase 3 Recruiting
Clinical Trials
11 trialsNCT06298565 2026-02-17
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
argenx
Recruiting
NCT06299748 2026-02-17
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
argenx
Recruiting
NCT07072988 2025-09-24
OPTIMAGE
Centre Hospitalier Universitaire de Nice
Phase 4 Recruiting
NCT06765161 2025-07-29
Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
Clinique Neuro-Outaouais
Phase 3 Recruiting
NCT06587867 2024-09-19
Seronegative Myasthenia Gravis - Efgartigimod IV
University Health Network, Toronto
Phase 3 Recruiting
NCT02965573 2024-08-28
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
argenx
Phase 2 Completed
NCT06221501 2024-01-24
Perioperative Efgartigimod for Thymoma and Myasthenia Gravis
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT03770403 2023-07-14
ADAPT+
argenx
Phase 3 Completed
NCT04777734 2022-04-29
Efgartigimod Expanded Access for Generalized Myasthenia Gravis
argenx
Approved for marketing
NCT03669588 2022-02-08
ADAPT
argenx
Phase 3 Completed